Heron Therapeutics Inc (NASDAQ:HRTX) traded with a subtraction of -$0.03 to $0.96 on Thursday, a downside of -3.54 percent. An average of 1,705,746 shares of common stock have been traded in the last five days. There was a fall of -$0.1356 in the past week, and it reached a new high 3 times over the past 12 months. The last 20 days have seen an average of 1,508,031 shares traded, while the 50-day average volume stands at 1,979,993.
HRTX stock has decreased by -42.07% in the last month. The company shares reached their 1-month lowest point of $0.9313 on 09/28/23. With the stock rallying to its 52-week high on 01/18/23, shares of the company touched a low of $0.95 and a high of $4.68 in 52 weeks. It has reached a new high 7 times so far this year and lost -61.77% or -$1.5556 in price. In spite of this, the price is down -79.58% from the 52-week high.
Valuation Metrics
Heron Therapeutics Inc (HRTX) has a trailing price-to-earnings (P/E) ratio of N/A for the broader industry. The stock’s beta is 1.08. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 1.14.
Financial Health
The quick ratio of Heron Therapeutics Inc for the three months ended June 29 was 1.39, and the current ratio was 1.91, indicating that the company is able to meet its debt obligations. Its gross profit as reported stood at $52.8 million compared to revenue of $107.67 million.
Earnings Surprise
In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$42.06 million in the quarter, while revenues of -$32.77 million were shrunk -34.0%. The analyst consensus anticipated Heron Therapeutics Inc’s latest quarter earnings to come in at -$0.23 per share, but it turned out to be -$0.35, a -52.20% surprise. For the quarter, EBITDA amounted to -$41.97 million. Shareholders own equity worth $140.76 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Heron Therapeutics Inc (HRTX) price momentum. RSI 9-day as of the close on 27 September was 16.98%, suggesting the stock is oversold, with historical volatility in this time frame at 34.47%.
As of today, HRTX’s price is $0.9853 -12.56% or -$0.1356 from its 5-day moving average. HRTX is currently trading -44.12% lower than its 20-day SMA and -61.77% lower than its 100-day SMA. However, the stock’s current price level is -37.04% below the SMA50 and -64.76% below the SMA200.
The stochastic %K and %D were 8.30% and 7.93%, respectively, and the average true range (ATR) was 0.0840. With the 14-day stochastic at 3.21% and the average true range at 0.0938, the RSI (14) stands at 23.99%. The stock has reached -0.0689 on the 9-day MACD Oscillator while the 14-day reading was at -0.1470.
Analyst Ratings
Guggenheim launched coverage on Heron Therapeutics Inc (NASDAQ: HRTX) in its analyst report released on May 27, 2020. The firm assigned the stock a Buy rating. The consensus rating for Heron Therapeutics Inc (HRTX) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell HRTX, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 6 others rate it as a “buy”.
What is HRTX’s price target for the next 12 months?
Analysts predict a range of price targets between $5.00 and $10.00, with a median target of $8.00. Taking a look at these predictions, the average price target given by analysts for Heron Therapeutics Inc (HRTX) stock is $7.75.
